#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Mersedeh Miraliakbari Email
VP, Regulatory Affairs . Nabriva Therapeutics plc
Dublin,
Locationm********************@nabriva.com
Primary EmailHow to contact Mersedeh Miraliakbari
Join and see Mersedeh's contact info for free!Current Roles
Employees:
50Revenue:
$22.1MAbout
Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. Nabriva was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna, Austria and commenced operations in February 2006. The new organization included small molecule assets, including pleuromutilin structure activity relationships (SAR) knowledge and was focused on synthesis of pleuromutilins for systemic human use. Following identification of our lead compound lefamulin and based on the clinical results of lefamulin for Acute Skin and Skin Structure Infections. We believed that targeted in vitro spectrum of activity for the common pathogens causing Community Acquired Bacterial Pneumonia (CABP), would allow us to develop lefamulin as the first pleuromutilin IV and oral antibiotic for human systemic administration for CABP. In 2014, we opened our US office in King of Prussia, Pennsylvania and completed an IPO on the NASDAQ under the ticker NBRV in September 2015. In June 2017 we redomiciled our corporate headquarters to Dublin, Ireland. We reported positive top-line efficacy and favorable tolerability data from the LEAP 1 Phase 3 trial in September of 2017. Additionally, based on current projections, we continue to expect to complete patient enrollment for LEAP 2 in the fourth quarter of 2017 and anticipate receiving top-line data for LEAP 2 in the spring of 2018. If the results of these trials are favorable, including achievement of the primary efficacy endpoints of the trials, we expect to submit applications for marketing approval for lefamulin for the treatment of CABP in both the United States and Europe in the second half of 2018. As of July 15, 2017 Nabriva employed 66 employees at its headquarters in Dublin, Ireland and at its locations in Vienna, Austria and King of Prussia, Pennsylvania, United States.Nabriva Therapeutics plc Address
414 Commerce DriveDublin, null
IE